Alcon Inc. Ordinary Shares (ALC) — Analysis Summary
Alcon Inc. Ordinary Shares (ALC) has a market cap of $32.61B with year-over-year revenue growth of +4.9%. Net margin stands at 9.4%. The stock trades at a P/E ratio of 33.3.
Key Takeaways
- Revenue changed +4.9% year-over-year
- Net margin of 9.4%
- P/E ratio of 33.3
Compared with its sector, ALC posted revenue growth of +4.9% and trades at a P/E of 33.3.
Alcon Inc. Ordinary Shares (ALC)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Employees
25,942
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.28
Dividend Yield
0.42%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.